PriceTargets.com logo

Pacira BioSciences - PCRX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $23.50
  • Forecasted Upside: 35.60%
  • Number of Analysts: 10
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$17.33 As of 12/3/2024 12:25 PM ET
▼ -0.48 (-2.70%)

This chart shows the closing price for PCRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pacira BioSciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PCRX

Analyst Price Target is $23.50
▲ +35.60% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Pacira BioSciences in the last 3 months. The average price target is $23.50, with a high forecast of $57.00 and a low forecast of $8.00. The average price target represents a 35.60% upside from the last price of $17.33.

This chart shows the closing price for PCRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 10 contributing investment analysts is to hold stock in Pacira BioSciences. This rating has held steady since August 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/11/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/9/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/8/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/7/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/5/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
9/3/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
11/2/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
12/2/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/12/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$25.00 ➝ $17.00
11/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
11/7/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$15.00 ➝ $16.00
10/4/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$14.00 ➝ $15.00
9/24/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$15.00 ➝ $18.00
8/13/2024Truist FinancialDowngradeBuy ➝ Sell$30.00 ➝ $8.00
8/12/2024Piper SandlerDowngradeOverweight ➝ Neutral$42.00 ➝ $11.00
8/12/2024Raymond JamesDowngradeOutperform ➝ Market Perform
8/12/2024Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$37.00 ➝ $14.00
8/12/2024JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Underweight$45.00 ➝ $10.00
8/12/2024Needham & Company LLCLower TargetBuy ➝ Buy$43.00 ➝ $22.00
8/12/2024HC WainwrightLower TargetBuy ➝ Buy$57.00 ➝ $39.00
7/31/2024Raymond JamesLower TargetOutperform ➝ Outperform$41.00 ➝ $37.00
7/31/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$42.00 ➝ $37.00
7/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
7/25/2024Truist FinancialLower TargetBuy ➝ Buy$45.00 ➝ $30.00
7/3/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$42.00 ➝ $42.00
7/3/2024BarclaysDowngradeOverweight ➝ Equal Weight$38.00 ➝ $25.00
7/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$57.00 ➝ $57.00
7/2/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$43.00 ➝ $43.00
5/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$57.00
5/8/2024BarclaysLower TargetOverweight ➝ Overweight$40.00 ➝ $38.00
5/8/2024Needham & Company LLCLower TargetBuy ➝ Buy$45.00 ➝ $43.00
4/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00
3/7/2024JPMorgan Chase & Co.Initiated CoverageOverweight$80.00 ➝ $45.00
3/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$57.00
3/1/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$53.00 ➝ $45.00
3/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$45.00
2/8/2024WedbushReiterated RatingOutperform ➝ Outperform$57.00
1/5/2024WedbushReiterated RatingOutperform$57.00
12/20/2023Raymond JamesInitiated CoverageOutperform$42.00
11/6/2023HC WainwrightLower TargetBuy ➝ Buy$63.00 ➝ $57.00
11/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$50.00 ➝ $42.00
11/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$67.00 ➝ $58.00
11/3/2023Needham & Company LLCLower TargetBuy ➝ Buy$52.00 ➝ $45.00
10/23/2023BarclaysLower TargetOverweight ➝ Overweight$60.00 ➝ $57.00
10/3/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$68.00
8/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$60.00 ➝ $50.00
8/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$70.00 ➝ $68.00
8/3/2023Needham & Company LLCLower TargetBuy ➝ Buy$60.00 ➝ $52.00
8/3/2023Truist FinancialLower TargetBuy ➝ Buy$60.00 ➝ $55.00
8/3/2023TD CowenUpgradeMarket Perform ➝ Outperform$50.00
8/3/2023HC WainwrightLower TargetBuy ➝ Buy$68.00 ➝ $63.00
7/13/2023HC WainwrightLower Target$71.00 ➝ $68.00
4/25/2023Piper SandlerLower Target$63.00 ➝ $62.00
4/20/2023Needham & Company LLCReiterated RatingBuy$60.00
3/3/2023BarclaysLower Target$90.00 ➝ $80.00
3/1/2023Royal Bank of CanadaLower TargetOutperform$80.00 ➝ $76.00
3/1/2023HC WainwrightBoost TargetBuy$69.00 ➝ $71.00
2/28/2023Needham & Company LLCLower TargetBuy$63.00 ➝ $60.00
2/10/2023HC WainwrightLower TargetBuy$76.00 ➝ $69.00
1/31/2023WedbushReiterated RatingOutperform$60.00
1/18/2023Truist FinancialLower Target$68.00 ➝ $63.00
1/6/2023BMO Capital MarketsLower TargetMarket Perform$60.00 ➝ $52.00
1/6/2023Needham & Company LLCLower TargetBuy$66.00 ➝ $63.00
12/21/2022WedbushReiterated RatingBuy$88.00
12/14/2022CowenLower Target$54.00 ➝ $50.00
12/14/2022CowenLower Target$54.00 ➝ $50.00
11/7/2022BMO Capital MarketsLower TargetMarket Perform$66.00 ➝ $60.00
11/4/2022HC WainwrightLower TargetBuy$83.00 ➝ $76.00
11/3/2022Needham & Company LLCLower TargetBuy$76.00 ➝ $74.00
10/21/2022Jefferies Financial GroupInitiated CoverageBuy$66.00
9/21/2022WedbushReiterated RatingOutperform$94.00
7/21/2022Piper SandlerLower TargetOverweight$84.00 ➝ $80.00
6/15/2022Needham & Company LLCLower TargetBuy$84.00 ➝ $76.00
3/1/2022Northland SecuritiesBoost Target$61.00 ➝ $67.00
2/26/2022WedbushReiterated RatingBuy$97.00 ➝ $94.00
2/25/2022HC WainwrightBoost TargetBuy$86.00 ➝ $90.00
2/16/2022WedbushReiterated RatingBuy$97.00
1/19/2022BarclaysBoost TargetOverweight$92.00 ➝ $96.00
1/7/2022WedbushReiterated RatingBuy$97.00
1/4/2022Northland SecuritiesBoost Target$57.00 ➝ $61.00
1/3/2022JPMorgan Chase & Co.Initiated CoverageOverweight$83.00
11/5/2021BarclaysBoost TargetOverweight$91.00 ➝ $92.00
11/4/2021HC WainwrightBoost TargetBuy$80.00 ➝ $86.00
10/18/2021Needham & Company LLCBoost TargetBuy$80.00 ➝ $84.00
10/12/2021HC WainwrightLower TargetBuy$84.00 ➝ $80.00
10/12/2021BMO Capital MarketsLower TargetMarket Perform$66.00 ➝ $60.00
10/5/2021Northland SecuritiesLower TargetMarket Perform$66.00 ➝ $57.00
10/1/2021BarclaysLower TargetOverweight$95.00 ➝ $91.00
9/22/2021WedbushReiterated RatingBuy$93.00
8/4/2021HC WainwrightLower TargetBuy$86.00 ➝ $84.00
7/26/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$70.00 ➝ $75.00
7/14/2021HC WainwrightReiterated RatingBuy$86.00
5/10/2021BMO Capital MarketsLower TargetMarket Perform$72.00 ➝ $70.00
5/5/2021Northland SecuritiesLower TargetMarket Perform$75.00 ➝ $66.00
4/9/2021Berenberg BankInitiated CoverageBuy$93.00
3/1/2021HC WainwrightBoost TargetBuy$70.00 ➝ $86.00
2/26/2021BarclaysBoost TargetOverweight$79.00 ➝ $94.00
2/11/2021Northland SecuritiesDowngradeOutperform ➝ Market Perform$72.00 ➝ $75.00
1/25/2021Northland SecuritiesBoost TargetOutperform$67.00 ➝ $72.00
1/21/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$63.00 ➝ $75.00
1/20/2021Piper SandlerBoost TargetOverweight$65.00 ➝ $90.00
1/8/2021Needham & Company LLCBoost TargetBuy$67.00 ➝ $76.00
1/6/2021Royal Bank of CanadaBoost TargetOutperform$65.00 ➝ $70.00
12/14/2020BarclaysBoost TargetOverweight$73.00 ➝ $79.00
12/9/2020Needham & Company LLCLower TargetBuy$68.00 ➝ $67.00
11/2/2020WedbushLower TargetOutperform$85.00 ➝ $83.00
10/7/2020WedbushReiterated RatingBuy$85.00
9/30/2020Jefferies Financial GroupBoost Target$69.00 ➝ $75.00
9/21/2020Northland SecuritiesUpgradeMarket Perform ➝ Outperform$58.00 ➝ $67.00
9/9/2020Needham & Company LLCBoost TargetBuy$64.00 ➝ $68.00
8/17/2020WedbushReiterated RatingBuy$85.00
8/14/2020Truist FinancialBoost Target$54.00 ➝ $65.00
8/10/2020HC WainwrightBoost TargetBuy$68.00 ➝ $70.00
7/20/2020WedbushReiterated RatingBuy$85.00
7/13/2020HC WainwrightReiterated RatingBuy$63.00 ➝ $68.00
7/10/2020Jefferies Financial GroupBoost TargetBuy$53.00 ➝ $69.00
7/6/2020Needham & Company LLCBoost TargetBuy$52.00 ➝ $64.00
7/6/2020Piper SandlerBoost TargetPositive ➝ Overweight$49.00 ➝ $65.00
7/2/2020WedbushReiterated RatingBuy$85.00
7/1/2020Royal Bank of CanadaBoost TargetOutperform$56.00 ➝ $62.00
6/30/2020Leerink PartnersBoost TargetOutperform$45.00 ➝ $58.00
6/30/2020Northland SecuritiesBoost TargetMarket Perform$50.00 ➝ $54.00
5/27/2020Northland SecuritiesDowngradeOutperform ➝ Market Perform
5/26/2020GuggenheimInitiated CoverageNeutral
5/13/2020Royal Bank of CanadaReiterated RatingBuy$56.00
5/12/2020WedbushReiterated RatingBuy$85.00
5/8/2020Leerink PartnersBoost TargetBuy$44.00 ➝ $45.00
5/7/2020Stifel NicolausLower TargetHold$49.00 ➝ $48.00
4/30/2020Needham & Company LLCLower TargetBuy$56.00 ➝ $52.00
4/27/2020WedbushReiterated RatingBuy$85.00
4/17/2020Northland SecuritiesReiterated RatingBuy$50.00
4/7/2020Northland SecuritiesInitiated CoverageOutperform$50.00
3/23/2020Piper SandlerLower Target$60.00 ➝ $49.00
3/23/2020Royal Bank of CanadaLower TargetOutperform$65.00 ➝ $56.00
3/20/2020Leerink PartnersUpgradeMarket Perform ➝ Outperform$46.00 ➝ $44.00
2/24/2020HC WainwrightBoost TargetBuy$60.00 ➝ $63.00
2/20/2020WedbushReiterated RatingBuy$85.00
2/20/2020Stifel NicolausReiterated RatingHold$49.00
2/20/2020Piper SandlerBoost TargetBuy$54.00 ➝ $60.00
1/23/2020SunTrust BanksInitiated CoverageBuy$60.00
1/7/2020WedbushReiterated RatingBuy$85.00
12/18/2019Royal Bank of CanadaReiterated RatingBuy
12/17/2019WedbushReiterated RatingBuy$85.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

0.80 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 10 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 15 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 5 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 18 very positive mentions
  • 11 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
9/4/2024
  • 12 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 8 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 18 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 18 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Pacira BioSciences logo
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Read More

Today's Range

Now: $17.33
Low: $17.02
High: $17.94

50 Day Range

MA: $16.53
Low: $13.91
High: $17.81

52 Week Range

Now: $17.33
Low: $11.16
High: $35.95

Volume

109,631 shs

Average Volume

839,739 shs

Market Capitalization

$800.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Pacira BioSciences?

The following Wall Street sell-side analysts have issued research reports on Pacira BioSciences in the last twelve months: Barclays PLC, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Raymond James, Royal Bank of Canada, StockNews.com, TheStreet, Truist Financial Co., and Wedbush.
View the latest analyst ratings for PCRX.

What is the current price target for Pacira BioSciences?

0 Wall Street analysts have set twelve-month price targets for Pacira BioSciences in the last year. Their average twelve-month price target is $23.50, suggesting a possible upside of 35.6%. Wedbush has the highest price target set, predicting PCRX will reach $57.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $8.00 for Pacira BioSciences in the next year.
View the latest price targets for PCRX.

What is the current consensus analyst rating for Pacira BioSciences?

Pacira BioSciences currently has 2 sell ratings, 4 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PCRX, but not buy more shares or sell existing shares.
View the latest ratings for PCRX.

What other companies compete with Pacira BioSciences?

Other companies that are similar to Pacira BioSciences include Supernus Pharmaceuticals, Omeros, Nektar Therapeutics, Assembly Biosciences and Cumberland Pharmaceuticals. Learn More about companies similar to Pacira BioSciences.

How do I contact Pacira BioSciences' investor relations team?

Pacira BioSciences' physical mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company's listed phone number is (813) 553-6680 and its investor relations email address is [email protected]. The official website for Pacira BioSciences is www.pacira.com. Learn More about contacing Pacira BioSciences investor relations.